3 Chronic Therapy Brands, Biotech Development Services and Ingredients and Formulations Stocks With a Strong Future Roadmap: Eris Lifesciences, Anthem Biosciences and Laurus Labs

Domestic brand and biotech outsourcing stocks let investors follow companies that sell chronic care brands and those that develop and make drugs for global partners. Eris Lifesciences, Anthem Biosciences and Laurus Labs cover chronic therapy brands, biotech development services, and ingredients and formulations.

This list covers three domestic brand and biotech outsourcing stocks with complete current figures: Eris Lifesciences, Anthem Biosciences and Laurus Labs. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Domestic Brand and Biotech Outsourcing Stocks?

Domestic brand and biotech outsourcing stocks are listed pharmaceutical companies that sell prescription brands in India or provide research, development and manufacturing services to global drug makers. Their earnings depend on prescriptions, contract wins and capacity.

Domestic Brand and Biotech Outsourcing Stocks at a Glance

On valuation, Eris Lifesciences trades at a P/E below the industry P/E, while Anthem Biosciences and Laurus Labs trade above it, which reflects the growth the market already expects. Readers comparing domestic brand and biotech outsourcing stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Domestic Brand and Biotech Outsourcing Stocks Have a Strong Roadmap in India?

Domestic brand and biotech outsourcing stocks have a strong roadmap in India because chronic disease is rising at home and global drug makers are outsourcing more research and production to Indian partners.

• Chronic care demand. More patients need long-term cardiac and diabetes therapy.
• Outsourcing trend. Global firms are handing development work to specialists.
• Capacity additions. New plants support larger contracts.

Why Eris Lifesciences Features Among These Domestic Brand and Biotech Outsourcing Stocks

Among the domestic brand and biotech outsourcing stocks on this list, Eris Lifesciences is an Indian pharmaceutical company with branded formulations in chronic therapies such as cardiac, diabetes and gastro-intestinal care, along with an injectables business.

The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0.

Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore.

Roadmap: Its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

What to watch: Check how smoothly acquired brands are integrated and how the injectables unit scales.

Why Anthem Biosciences Features Among These Domestic Brand and Biotech Outsourcing Stocks

Among the chronic therapy brand shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.

Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.

The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.

Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.

Why Laurus Labs Features Among These Domestic Brand and Biotech Outsourcing Stocks

Among the three companies on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.

In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%.

Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.

Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.

Eris Lifesciences vs Anthem Biosciences vs Laurus Labs on Key Financials

The table below sets the three domestic brand and biotech outsourcing stocks side by side on revenue, profit and margin, using reported figures.

Anthem Biosciences posts the highest return on equity in this group at 19.4%. Laurus Labs has the largest FY26 revenue at Rs 6,868 crore, and Eris Lifesciences shows the fastest revenue growth with a 22.9% compound annual rate. A useful habit with domestic brand and biotech outsourcing stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Domestic Brand and Biotech Outsourcing Stocks

Every theme carries risks that deserve a check before any decision. For these domestic brand and biotech outsourcing stocks, the main points are: Long-term chronic therapy brand shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Customer concentration. A few large customers can shape contract revenue.
• Approval timelines. Launches depend on regulatory decisions that can shift.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter domestic brand and biotech outsourcing stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Domestic Brand and Biotech Outsourcing Stocks

Domestic brand and biotech outsourcing stocks reward investors who follow prescriptions, contract wins and capacity together. Eris Lifesciences, Anthem Biosciences and Laurus Labs each take a different route to growth. Based on the 21 October 2026 close, Eris Lifesciences trades at Rs 1,136.3, Anthem Biosciences at Rs 805.55 and Laurus Labs at Rs 2,012.5.

Download the Univest iOS App or Univest Android App to track domestic brand and biotech outsourcing stocks, set price alerts and get research-backed stock ideas.

What are domestic brand and biotech outsourcing stocks?

Ans. Domestic brand and biotech outsourcing stocks are listed pharmaceutical companies that sell prescription brands in India or provide research, development and manufacturing services to global drug makers. Their earnings depend on prescriptions, contract wins and capacity. This list looks at three of them, Eris Lifesciences, Anthem Biosciences and Laurus Labs, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which domestic brand and biotech outsourcing stocks are covered in this list?

Ans. This list covers Eris Lifesciences, Anthem Biosciences and Laurus Labs. Based on the 21 October 2026 close, Eris Lifesciences traded at Rs 1,136.3, Anthem Biosciences at Rs 805.55 and Laurus Labs at Rs 2,012.5. Their return on equity ranges from 15.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 22.9%.

Why do domestic brand and biotech outsourcing stocks have a strong future roadmap in India?

Ans. Domestic brand and biotech outsourcing stocks have a strong roadmap in India because chronic disease is rising at home and global drug makers are outsourcing more research and production to Indian partners. The main drivers are as follows. Chronic care demand. More patients need long-term cardiac and diabetes therapy. Outsourcing trend. Global firms are handing development work to specialists. Capacity additions. New plants support larger contracts. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Eris Lifesciences performed financially?

Ans. Revenue rose from Rs 1,373 crore in FY22 to Rs 3,137 crore in FY26, a compound annual growth rate of 22.9%. Net profit grew from Rs 406 crore in FY22 to Rs 648 crore in FY26, which works out to a compound annual growth rate of 12.4%. In the June 2026 quarter, revenue grew 12.9% year on year to Rs 876 crore, while net profit rose 14.6% to Rs 143 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 0.60 and a market capitalisation of Rs 15,618 crore. The stock trades at a P/E of 23.5, below the industry P/E of 36.0. Looking ahead, its portfolio expansion, including the addition of branded domestic formulations from other companies and its injectables unit, widens its reach with doctors. Chronic therapy brands bring repeat prescriptions, which supports steady revenue.

How has Anthem Biosciences performed financially?

Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.

How has Laurus Labs performed financially?

Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.

What risks should investors check before buying domestic brand and biotech outsourcing stocks?

Ans. Investors should check a few risks before buying domestic brand and biotech outsourcing stocks. Customer concentration. A few large customers can shape contract revenue. Approval timelines. Launches depend on regulatory decisions that can shift. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of domestic brand and biotech outsourcing stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.